Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 5 selected

Guidance programme

Area of interest

Showing 21 to 30 of 1233

TitleReference numberPublishedLast updated
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)TA1141
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatmentTA1139
Pegzilarginase for treating arginase-1 deficiency in people 2 years and overHST35
Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancerTA1138
Hypertension in adults: diagnosis and managementNG136
Blood transfusionNG24
Molnupiravir for treating COVID-19TA1056
Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19TA878
Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancerTA1136
Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)TA1137

Results per page

  1. 10
  2. 25
  3. 50
  4. All